Diagnosis and Management of von Willebrand Disease
Introduction to von Willebrand Disease
- Von Willebrand disease (VWD) is a bleeding disorder affecting approximately 1% of the general population, characterized by a deficiency or dysfunction of von Willebrand factor (VWF), which plays a crucial role in platelet adhesion and aggregation, and carries and stabilizes blood coagulation factor VIII in circulation 1
- VWD can be classified into three main types: Type 1 (partial quantitative deficiency, ~75% of cases), Type 2 (qualitative deficiency with four subtypes), and Type 3 (virtually complete quantitative deficiency, rare, ~1 in 1,000,000) 1
Diagnosis and Testing
- The American Academy of Pediatrics notes that VWF testing may need to be repeated up to 3 times to ensure reliable results, as VWF levels can be falsely elevated in response to clinical status, masking underlying defects 2
- A ratio of VWF:RCo to VWF:Ag below 0.5-0.7 suggests qualitative VWD (Type 2) even if individual values appear normal 1
- VWF multimer analysis is valuable when clinical suspicion is high, but not recommended for initial screening 1
- Repeat testing during non-stress periods is recommended, as VWF is an acute phase reactant 2
- The following table summarizes the RIPA characteristics for different subtypes of von Willebrand disease:
| Subtype | Key Laboratory Findings | RIPA Characteristics |
|---|---|---|
| Type 2A | VWF:RCo <30 IU/dL, VWF:Ag 30-200 IU/dL, VWF:RCo/VWF:Ag <0.5-0.7, Loss of high & intermediate MW multimers | May be normal at low-dose |
| Type 2B | VWF:RCo <30 IU/dL, VWF:Ag 30-200 IU/dL, VWF:RCo/VWF:Ag <0.5-0.7, Loss of high MW multimers | Usually enhanced at low-dose, but can be normal |
| Type 2M | VWF:RCo <30 IU/dL, VWF:Ag 30-200 IU/dL, VWF:RCo/VWF:Ag <0.5-0.7, Normal multimer pattern | Often normal at low-dose |
| Type 2N | Normal VWF:RCo and VWF:Ag, Low FVIII:C, Normal VWF:RCo/VWF:Ag ratio, Reduced VWF:FVIII binding | Resembles mild hemophilia A |
- The American Society of Hematology recommends laboratory tests, including complete blood count (CBC), prothrombin time (PT), and activated partial thromboplastin time (PTT), when clinical evaluation suggests a bleeding disorder 1
- For patients with a strong mucocutaneous bleeding history, the American Society of Hematology recommends ordering three core tests: VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), and factor VIII coagulant activity (FVIII) 1
Clinical Evaluation
- Key clinical evaluation points include documenting frequency and severity of bleeding episodes, assessing for thrombocytopenia, reviewing family history for bleeding disorders, and noting conditions that might cause acquired von Willebrand syndrome, according to the American Society of Hematology 1
- Clinical evaluation should look for signs of ecchymoses, hematomas, petechiae, evidence of liver disease, splenomegaly, joint and skin laxity, telangiectasia, signs of anemia, and anatomic lesions on gynecologic examination, as suggested by the American Society of Hematology 1
- Conditions like Ehlers-Danlos syndrome or scurvy should be considered when evaluating easy bruising, in addition to arteriovenous malformations, as suggested by the American Academy of Pediatrics 2
- Medication use, including anticoagulants, NSAIDs, and certain supplements, should be documented as it can affect test results, particularly platelet function tests, according to the American Academy of Pediatrics 2
Treatment and Management
- Desmopressin (DDAVP) is recommended as the first-line treatment for patients with mild to moderate Type 1 von Willebrand disease, while VWF-containing factor concentrates are recommended for Type 2B, Type 3, and severe forms of Type 1 and 2 VWD, as recommended by the American Society of Hematology 3
- DDAVP promotes the release of VWF and FVIII from the endothelium, according to the American Heart Association, and VWF-containing factor concentrates are indicated for severe forms of Type 1 VWD, Type 2B VWD, and when DDAVP is ineffective 4, 5
- For surgical procedures, a target VWF activity level of ≥50 IU/dL is recommended, as suggested by the International Society on Thrombosis and Haemostasis, and monitor VWF:RCo and FVIII:C levels at 12-24 hours post-surgery and maintain VWF:RCo >50 IU/dL for 72 hours after major surgery 6, 5, 7
- Close monitoring during pregnancy and target VWF:RCo ≥50 IU/dL for vaginal delivery and ≥80 IU/dL for cesarean section are recommended by the Royal College of Obstetricians and Gynaecologists 8, 6
- Consultation with a hematologist is recommended for patients with a strong family history of VWD, as suggested by the American Academy of Pediatrics, and prophylactic treatment is essential for patients with known bleeding disorders, and targeted factor replacement is preferred over indiscriminate use of FFP 2, 9
- Balance hemostasis with thrombosis risk, especially in older patients, and document response to interventions to guide future management, as recommended by the American Society of Anesthesiologists, and concomitant use of aspirin or other platelet antiaggregants with metoclopramida should be strictly avoided 5, 10
- The use of metoclopramida in patients with acquired von Willebrand syndrome may worsen platelet dysfunction, according to the American Society of Hematology 11